37 min listen
New Targeted Treatments for Breast Cancer — Conversation with Dr. Carlos Doti, VP, US Medical Affairs Oncology, AstraZeneca
New Targeted Treatments for Breast Cancer — Conversation with Dr. Carlos Doti, VP, US Medical Affairs Oncology, AstraZeneca
ratings:
Length:
22 minutes
Released:
Feb 7, 2024
Format:
Podcast episode
Description
This episode features an interview with Carlos Doti, MD, Vice President, US Medical Affairs Oncology, AstraZeneca, about new breast cancer treatments.Recently, AstraZeneca won approval for the company’s AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1, or PTEN). The approval of Truqap was the first-in-class approval for AstraZeneca.Dr. Doti is a haematologist by training and is passionate about aiming to deliver treatments that have a real impact for people living with cancer across every aspect of their disease. Dr. Doti has worked in industry for the last 14 years, including seven years at AstraZeneca in various roles, and in small markets like Argentina as well as larger global markets. Since 2022, Dr. Doti has been focusing on the US market in areas including hematology and oncology, working in breast, lung, GI and gynecological cancers among others. Tune into the episode to hear more about the milestone approval of the new combination breast cancer treatment, which has been a much-needed treatment option for the nearly 50 percent of patients with advanced HR-positive breast cancer who have PIK3CA and AKT1 mutations or PTEN alterations, and experience resistance to first-line treatments such as endocrine therapies and CDK 4/6 inhibitors. For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Released:
Feb 7, 2024
Format:
Podcast episode
Titles in the series (100)
Epigenetic Editing with CRISPR + ADHD in Preschoolers by Xtalks Life Science Podcast